Prescription medicine
Orforglipron Brand names: Foundayo
Orforglipron (Foundayo) is a prescription medicine with an FDA approval on record since 2026. No generic is listed; pharmacies paid $20.89 per Foundayo 0.8 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
- Boxed warning
Check it at the source: the orforglipron FDA label on DailyMed (effective July 29, 2026, Eli Lilly and Company); the NDA 220934 record on Drugs@FDA; every orforglipron label on DailyMed.
Highlights of the record
FDA label of July 29, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
RISK OF THYROID C-CELL TUMORS.
In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents [see Nonclinical Toxicology ( 13.1 )]. While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )]. FOUNDAYO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )]. Counsel patients regarding the potential risk for MTC with the use of FOUNDAYO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with FOUNDAYO [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )]. […]
Used for
From the label: indications and usageFOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
Forms and strengths
- 0.8 mg
- 2.5 mg
- 5.5 mg
- 9 mg
- 14.5 mg
- 17.2 mg
Film-coated tablet.
On the market
- Earliest approval on file
- April 1, 2026 Foundayo, Eli Lilly And Co; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- September 26, 2037 Foundayo tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $20.89 per tablet Foundayo 0.8 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 726 through July 30, 2026
What is orforglipron used for?
From the label: indications and usageFOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. […]
Conditions named in the indications of orforglipron's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: GLP-1 Receptor Agonist.
Source: FDA drug label (FOUNDAYO), Eli Lilly and Company, effective July 29, 2026 (SPL set 8ac446c5-feba-474f-a103-23facb9b5c62), via openFDA; the full label on DailyMed
What does the patient leaflet for orforglipron say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about FOUNDAYO?FOUNDAYO may cause serious side effects including: Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, medicines that work like FOUNDAYO caused thyroid tumors, including thyroid cancer. It is not known if FOUNDAYO will cause thyroid tumors, or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Do not take FOUNDAYO if you or any of your family have ever had a type of thyroid cancer called MTC, or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
From the patient leaflet: How should I store FOUNDAYO?Store at room temperature between 68°F to 77°F (20°C to 25°C). Keep FOUNDAYO and all medicines out of the reach of children.
Source: FDA drug label (FOUNDAYO), Eli Lilly and Company, effective July 29, 2026 (SPL set 8ac446c5-feba-474f-a103-23facb9b5c62), via openFDA; the full label on DailyMed
Is there a generic for orforglipron (Foundayo)?
No generic orforglipron is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 1 patent for Foundayo tablets: the compound patent runs to September 26, 2037. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2026 earliest approval on file
- 2037 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for orforglipron (Foundayo)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $20.89 per Foundayo 0.8 mg tablet. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Foundayo 0.8 mg tablet | Brand | $20.89 per tablet | $626.78 | n/a |
| Foundayo 2.5 mg tablet | Brand | $20.84 per tablet | $625.11 | n/a |
| Foundayo 5.5 mg tablet | Brand | $20.82 per tablet | $624.57 | n/a |
| Foundayo 9 mg tablet | Brand | $20.85 per tablet | $625.61 | n/a |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the orforglipron label say about other medicines?
The orforglipron label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Liraglutide | warnings and precautions | Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans. |
| Ritonavir | drug interactions | Avoid concomitant use of FOUNDAYO with strong CYP3A4 inhibitors that also inhibit OATP1B (e.g., ritonavir) [see Dosage and Administration ( 2.2 )]. |
| Simvastatin | drug interactions | Intervention; Do not exceed simvastatin 20 mg once daily when concomitantly used with FOUNDAYO. |
Source: FDA drug label (FOUNDAYO), Eli Lilly and Company, effective July 29, 2026 (SPL set 8ac446c5-feba-474f-a103-23facb9b5c62), via openFDA; the full label on DailyMed
What do FAERS reports show for orforglipron?
The FDA Adverse Event Reporting System holds 726 reports that list orforglipron among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 10 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as orforglipron?
8 other medicines are given the same way (oral) and in the same FDA class as orforglipron or labeled mainly for the same use (weight management), the same class first. Weight management lists all 12 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Semaglutide | Weight management | none listed | $33.13 per tablet 1.5 mg tablet | A presentation being discontinued |
| Phentermine | Weight management | 27 labelers | $0.0727 per tablet 37.5 mg tablet | No current entry |
| Diethylpropion | Weight management | 13 labelers | $0.238 per tablet 25 mg tablet | No current entry |
| Phendimetrazine | Weight management | 11 labelers | $0.132 per tablet 35 mg tablet | No current entry |
| Phentermine and topiramate | Weight management | 2 labelers | $3.06 per capsule 7.5-46 mg capsule | No current entry |
| Benzphetamine | Weight management | 6 labelers | n/a | No current entry |
| Orlistat | Weight management | none listed | $7.00 per capsule 120 mg capsule | No current entry |
| Bupropion and naltrexone | Weight management | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as orforglipron
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to orforglipron
- 8 medicines for the same use
- Other GLP-1 receptor agonists
- the pharmacologic class, with prices and generics
- Orforglipron side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other